Drugs / ASP3772
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04525599 | Sep 2020 → Apr 2022 | pneumococcal infection | Affinivax, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04265911 | Feb → Nov 2020 | — | Affinivax, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03803202 | Jan 2019 → Sep 2020 | bacterial pneumonia, pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP3772 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04525599 ↗ |
| Modality | Vaccine | “novel 24-valent pneumococcal vaccine (ASP3772)” PMID 35690500 ↗ Jun 2022 |
| Route | Intramuscular | “Participants received a single dose of ASP3772 (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose) intramuscularly” NCT03803202 ↗ |